Foundation for Angelman Syndrome Therapeutics
http://www.cureangelman.org
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Foundation for Angelman Syndrome Therapeutics
With Hopeful Interim Data, Ultragenyx Bets On GeneTx, Angelman Syndrome Candidate
Ultragenyx is buying its Angelman syndrome partner GeneTx for $75m on the heels of an interim Phase I/II readout that shows signs of clinical activity and appears to resolve earlier safety worries.
Company Information
- Industry
- Academic and Research Institutions
- Other Names / Subsidiaries
-
- GeneTx Biotherapeutics LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Foundation for Angelman Syndrome Therapeutics
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice